ModerateVitamin K antagonist anticoagulants×Third-generation fluoroquinolone
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist, and both the originator and the generic SmPC list fluoroquinolones among the drugs that can potentiate its effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents do not explain how levofloxacin potentiates the anticoagulant. Levofloxacin does not inhibit CYP1A2, one of the enzymes that metabolise the more active R-enantiomer of acenocoumarol (levofloxacin and acenocoumarol SmPCs, AEMPS). In healthy volunteers it did not change the concentrations or disposition of R- and S-warfarin (levofloxacin prescribing information, US Food and Drug Administration, FDA). Even so, post-marketing reports describe levofloxacin potentiating the effect of warfarin, with raised prothrombin times accompanied by bleeding. Data exist only for warfarin (FDA). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. With levofloxacin and a vitamin K antagonist such as warfarin, reports describe a raised prothrombin time and international normalised ratio (INR) and bleeding, which may be serious (levofloxacin summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. When levofloxacin is combined with a vitamin K antagonist, acenocoumarol included, check the prothrombin time and the international normalised ratio (INR) (levofloxacin summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US levofloxacin label refers only to warfarin and asks for close monitoring of these tests and of signs of bleeding (levofloxacin prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a levofloxacin course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Levofloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 5c6c117c-9d91-48f4-9aaa-ee70b99218c2, version 3, 06/2026, section 5.11 (Prolongation of the QT Interval)
- AEMPS: Ficha técnica: Levofloxacino, Tavanic 500 mg (nº registro 62065), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62065 (Tavanic 500 mg comprimidos recubiertos con película, Sanofi Aventis), revisión 08/2026, secciones 4.3, 4.4, 4.5, 4.8 y 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9